Voon Hong Ong
Royal Free London NHS Foundation Trust · 256 works · 6,003 citations · h-index 38
Top works
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis
- BSR and BHPR guideline for the treatment of systemic sclerosis
- Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor β (TGFβ) Receptor Leads to Paradoxical Activation of TGFβ Signaling Pathways with Fibrosis in Transgenic Mice
- Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis
- Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma
- Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
- The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
- Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
- Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
- Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis
- Clinical and Serological Hallmarks of Systemic Sclerosis Overlap Syndromes
- The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis
- Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
- Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis.
- Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis
- Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: Evidence for autocrine regulation of myofibroblast differentiation
- Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis
- Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis
- The 2024 British Society for Rheumatology guideline for management of systemic sclerosis